BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cibinqo (abrocitinib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Cibinqo (abrocitinib)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07848074-1302@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Cibinqo (abrocitinib): Phase 4 readout est. (NCT07848074)
DESCRIPTION:Cibinqo (abrocitinib)\, phase 4\, Atopic Dermatitis.\nStudy: Ab
 rocitinib Dose Tapering in Patients With Atopic Dermatitis\nEstimated prim
 ary completion: 1 May 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/abrocitinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07848074
URL:https://assetmemo.bio/drug/abrocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06807268-1302@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270502
DTEND;VALUE=DATE:20270503
SUMMARY:Cibinqo (abrocitinib): Phase 3 readout est. (NCT06807268)
DESCRIPTION:Cibinqo (abrocitinib)\, phase 3.\nStudy: A Study of the Medicin
 e Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moder
 ate-to-Severe Eczema\nEstimated primary completion: 2 May 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/abrocitinib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06807268
URL:https://assetmemo.bio/drug/abrocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07242638-1302@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20290223
DTEND;VALUE=DATE:20290224
SUMMARY:Cibinqo (abrocitinib): Phase 2 readout est. (NCT07242638)
DESCRIPTION:Cibinqo (abrocitinib)\, phase 2\, Atopic Dermatitis.\nStudy: Tr
 eatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Indiv
 iduals With Down Syndrome\nEstimated primary completion: 23 February 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/abrocitinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07242638
URL:https://assetmemo.bio/drug/abrocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07823595-1302@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20290410
DTEND;VALUE=DATE:20290411
SUMMARY:Cibinqo (abrocitinib): Phase 3 readout est. (NCT07823595)
DESCRIPTION:Cibinqo (abrocitinib)\, phase 3\, Atopic Dermatitis.\nStudy: Ab
 rocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Year
 s of Age\nEstimated primary completion: 10 April 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/abrocitinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07823595
URL:https://assetmemo.bio/drug/abrocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07352566-1302@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Cibinqo (abrocitinib): Phase 4 readout est. (NCT07352566)
DESCRIPTION:Cibinqo (abrocitinib)\, phase 4\, Atopic Dermatitis.\nStudy: Ut
 ilization of a Microdevice for Psoriasis and Atopic Dermatitis\nEstimated 
 primary completion: 1 June 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/abrocitinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07352566
URL:https://assetmemo.bio/drug/abrocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06807281-1302@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20320222
DTEND;VALUE=DATE:20320223
SUMMARY:Cibinqo (abrocitinib): Phase 3 readout est. (NCT06807281)
DESCRIPTION:Cibinqo (abrocitinib)\, phase 3\, Atopic Dermatitis.\nStudy: A 
 Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Year
 s and Older With Moderate to Severe Eczema\nEstimated primary completion: 
 22 February 2032. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abr
 ocitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06807281
URL:https://assetmemo.bio/drug/abrocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
